RNA Therapy Ulefnersen Shows First-Ever Survival Benefit in Phase 3 Trial for Fatal Genetic ALS

The U.S. Food and Drug Administration and global health regulators will soon decide whether to approve the first targeted treatment for a rapid-onset, fatal form of amyotrophic lateral sclerosis (ALS). In the coming months, drugmakers Ionis Pharmaceuticals and Otsuka Pharmaceutical plan to submit data from a pivotal Phase 3 trial, asking agencies to grant expedited approval for their experimental RNA therapy, ulefnersen. If regulators clear the application, clinicians will have a disease-modifying intervention for a genetic condition that currently relies entirely on palliative care.[2][3]

The regulatory push follows the release of topline results from the FUSION trial, which tracked patients over a 72-week period. In a primary analysis of 73 participants, ulefnersen demonstrated a statistically significant improvement in a combined measure of physical function and survival compared to a placebo. The joint-rank analysis, measured from baseline to day 505, yielded a highly definitive efficacy signal (p=0.0005), confirming that the drug delayed the time until death or the need for permanent ventilation.[2][3][4]

Ulefnersen targets a specific genetic subtype known as FUS-ALS, caused by mutations in the fused in sarcoma (FUS) gene. While this variant accounts for only 0.6% of all ALS cases globally, it disproportionately strikes younger populations. According to Otsuka, FUS mutations drive an estimated 43% to 52% of pediatric and juvenile ALS cases, which typically progress much faster than adult-onset forms of the neurodegenerative disease.[2]

The therapy is an antisense oligonucleotide administered directly into the spinal fluid via an intrathecal injection. It works by binding to messenger RNA to block the production of the FUS protein, including the toxic mutant forms that cause motor neurons to rapidly degenerate. By halting this protein synthesis at the source, the drug preserves nerve function rather than merely managing the resulting symptoms.[4]

Beyond the primary clinical outcomes, blood tests from the trial confirmed the drug's biological mechanism. Patients receiving ulefnersen showed significant reductions in serum neurofilament light chain (NfL), a well-established biomarker that indicates active nerve cell damage. Lower NfL levels correlate directly with slowed neurodegeneration, providing regulators with objective biochemical evidence to support the clinical survival data.[2][3][4]

"Ulefnersen is the first investigational medicine to demonstrate a statistically significant benefit in a Phase 3 trial using a prespecified joint-rank analysis that combines assessments of function and survival," said Holly Kordasiewicz, chief development officer at Ionis. John Kraus, chief medical officer at Otsuka, noted that the data provides "compelling evidence that a targeted genetic approach may help alter the course of disease."[3][4][5]

For families facing a FUS-ALS diagnosis, the data offers a tangible shift in clinical management. However, ulefnersen is not a one-time cure; it requires ongoing spinal injections, and the trial reported mild to moderate adverse events associated with the treatment. Patients and caregivers will need to weigh the burden of repeated lumbar punctures against the proven survival benefits.[2][3]

While the FDA and the European Medicines Agency review the impending submissions, Otsuka has launched a global Early Access Program. This initiative allows eligible patients with confirmed FUS-ALS who cannot enroll in ongoing clinical trials to receive ulefnersen immediately. The commercial stakes are also solidifying; Otsuka previously paid Ionis $10 million upfront in 2024 to secure exclusive global rights to the therapy.[2][4]